ADDITIONAL INFORMATION CONTINUED EQUITY SECURITIES HELD BY DIRECTORS AS AT 22 MARCH 2024 Interests in Ordinary Shares Interests in Loan Funded Shares Director Direct Indirect Indirect Dr Trevor Scott 27,106 2,387,678 – Dianne Angus 30,000 – – Patrick Davies – 264,634 – Jenny Harry – 29,663 – Jonathan Pilcher1 – 398,207 1,500,000 Joe Basile 10,000 – – 1 Jon Pilcher has an interest in 1.5 million Loan Funded Shares held by Neuren Trustee Limited. As detailed in Note 13 to the Financial Statements, the Loan Funded Shares are subject to vesting conditions and repayment of a loan amounting to $1.84 per share ($2,760,000) before they can be transferred to Jon. DIRECTORS OF SUBSIDIARY COMPANIES AT 31 DECEMBER 2023 Jon Pilcher Larry Glass Dr Trevor Scott Neuren Pharmaceuticals Inc. √ √ Neuren Pharmaceuticals (Australia) Pty Ltd √ √ Neuren Trustee Limited √ AUSTRALIAN STOCK EXCHANGE DISCLOSURES Neuren Pharmaceuticals Limited is incorporated in New Zealand under the Companies Act 1993. The Company is not subject to Chapter 6, 6A, 6B and 6C of the Corporations Act, Australia, dealing with the acquisition of shares (such as substantial holdings and takeovers). Limitations on the acquisition of shares imposed under New Zealand law are as follows: (a) In general, securities in the Company are freely transferable and the only significant restrictions or limitations in relation to the acquisition of securities are those imposed by New Zealand laws relating to takeovers and overseas investment. (b) The New Zealand Takeovers Code creates a general rule under which the acquisition of 20% or more of the voting rights in the Company or the increase of an existing holding of 20% or more of the voting rights of the Company can only occur in certain permitted ways. These include a full takeover offer in accordance with the Takeovers Code, a partial takeover in accordance with the Takeovers Code, an acquisition approved by an ordinary resolution, an allotment approved by an ordinary resolution, a creeping acquisition (in certain circumstances), or compulsory acquisition of a shareholder holding 90% or more of the shares. (c) The New Zealand Overseas Investment Act 2005 and Overseas Investment Regulations 2005 (New Zealand) regulate certain investments in New Zealand by overseas interest. In general terms, the consent of the New Zealand Overseas Investment Office may be required where an ‘overseas person’ acquires shares in the Company that amount to 25 % or more of the shares issued by the Company, or if the overseas person already holds 25% or more, the acquisition increases that holding. EQUITY SECURITIES INFORMATION The Company has only one class of shares, being ordinary shares. Each ordinary share is entitled to one vote when a poll is called; otherwise on a show of hands at a shareholder meeting every member present in person or by proxy has one vote. There are no securities subject to escrow, there were no on-market purchases of securities during the reporting period and there is no current on–market buy–back of securities. The following information is based on share registry information processed up to and including 22 March 2024. The number of ordinary shareholdings held in less than marketable parcels at 22 March 2024 was 406, holding 3,296 ordinary shares. Neuren Pharmaceuticals Limited Annual Report 2023 56
RkJQdWJsaXNoZXIy MjE2NDg3